Upstream Bio Inc (UPB) Institutional Investor Snapshot (153 Funds, Q2 2026)

UPB ranks #3637 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

153 institutions disclose a position in UPB, but none treat it as a major bet — even Enavate Sciences GP, LLC, its most concentrated holder, allocates just 4.9% of its own portfolio to it.

JPMorgan has added to its UPB position for two straight quarters, increasing it by $4.0M to reach $7.0M today.

Fidelity has trimmed its UPB position for two straight quarters, cutting it by $147.6M while still holding $56.5M.

UPB is down 1.1% today, but institutions show net buying of $70.1M this quarter — a divergence between today's price move and the underlying institutional flow.

UPB reported a net loss of $156.5M over the trailing twelve months.

• Not yet profitable — net loss of $156.5M over the trailing twelve months
• Revenue grew 16.0% year over year
• Net income declined year over year, from -$104.5M to -$156.5M
• Operating cash flow was negative, using $133.3M in cash
• Current ratio of 26.15x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.04x equity — within a conventional range